What is a stock summary page? Click here for an overview.
Business Description
Akari Therapeutics PLC
NAICS : 325412
SIC : 2834
ISIN : US00972G1085
Share Class Description:
AKTX: ADRDescription
Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing therapies for autoimmune and inflammatory diseases involving the complement component 5 (C5) and leukotriene B4 (LTB4) pathways. The company's pipelines include HSCT-TMA and Geographic Atrophy (GA).
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.25 | |||||
| Equity-to-Asset | -2.45 | |||||
| Debt-to-Equity | -0.15 | |||||
| Debt-to-EBITDA | -0.04 | |||||
| Piotroski F-Score | N/A/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 32.9 | |||||
| 3-Year EPS without NRI Growth Rate | 45 | |||||
| 3-Year FCF Growth Rate | 32.1 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 89.07 | |||||
| 9-Day RSI | 81.77 | |||||
| 14-Day RSI | 73.43 | |||||
| 6-1 Month Momentum % | -69.88 | |||||
| 12-1 Month Momentum % | -46.99 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.29 | |||||
| Quick Ratio | 0.29 | |||||
| Cash Ratio | 0.24 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -50.9 | |||||
| Shareholder Yield % | -30.73 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROA % | -539.79 | |||||
| ROIC % | -821.33 | |||||
| 3-Year ROIIC % | 77.25 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | -1.44 | |||||
| EV-to-EBITDA | -1.44 | |||||
| EV-to-FCF | -2.59 | |||||
| Earnings Yield (Greenblatt) % | -69.44 | |||||
| FCF Yield % | -36.63 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:AKTX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Akari Therapeutics PLC Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -2.751 | ||
| Beta | 0.79 | ||
| 3-Year Sharpe Ratio | -0.92 | ||
| 3-Year Sortino Ratio | -1.16 | ||
| Volatility % | 102.91 | ||
| 14-Day RSI | 73.43 | ||
| 14-Day ATR ($) | 0.141111 | ||
| 20-Day SMA ($) | 1.0298 | ||
| 12-1 Month Momentum % | -46.99 | ||
| 52-Week Range ($) | 0.85 - 4.4 | ||
| Shares Outstanding (Mil) | 26.47 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Akari Therapeutics PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Akari Therapeutics PLC Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Akari Therapeutics PLC Frequently Asked Questions
What is Akari Therapeutics PLC(AKTX)'s stock price today?
The current price of AKTX is $1.53. The 52 week high of AKTX is $4.40 and 52 week low is $0.85.
When is next earnings date of Akari Therapeutics PLC(AKTX)?
The next earnings date of Akari Therapeutics PLC(AKTX) is 2025-04-01 Est..
Does Akari Therapeutics PLC(AKTX) pay dividends? If so, how much?
Akari Therapeutics PLC(AKTX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers